Articles from SNIPR BIOME

COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from new investors the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D) as well as existing investors Lundbeckfonden BioCapital, North-East Family Office and Wellington Partners.

COPENHAGEN, Denmark, June 12, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in its Phase 1b study of SNIPR001 in patients with hematological cancer who are undergoing hematopoietic stem-cell transplantation (HSCT).

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- SNIPR BIOME ApS (“SNIPR” or “the Company”), a clinical stage biotech company pioneering CRISPR-based therapies, today announces grant of patent EP4392563B on February 24th 2025 by the European Patent Office protecting the newly-discovered and characterised CRISPR-CasS™ system. This system and its uses do not rely on Cas9 or Cas3. The patent covers use of the new CasS system in both prokaryotic and eukaryotic cells, as well as when fused to effector domains conferring additional functionality, such as base editors and nuclease domains. Commercial licenses are available.

SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform to improve Environmental Enteric Dysfunction (EED) in pregnant women from low- and middle-income countries (LMICs).